Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intraluminal Mono-antibiotic Therapy for Helicobacter Pylori Infection - A Comparison of Levofloxacin Powder and Levofloxacin Solution

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03832465
Recruitment Status : Not yet recruiting
First Posted : February 6, 2019
Last Update Posted : February 15, 2019
Sponsor:
Information provided by (Responsible Party):
Tai-cherng Liou, MD, Mackay Memorial Hospital

Brief Summary:

Helicobacter pylori (H. pylori) is an important causal factor of chronic gastritis, peptic ulcer disease, gastric cancer and gastric lymphoma. The World Health Organization classified H. pylori as a Group 1 carcinogen in 1994. Endoscopic examination is indicated to confirm the above diagnosis for patient with H. pylori infection. The eradication of H. pylori can reduce the recurrence rate of peptic ulcer disease and even has the potential to prevent gastric cancer. H. pylori is the most common chronic bacterial infection in humans. The prevalence of H. pylori is about 30-50% in the Western adult population. It is estimated that about 50% of people are infected with this bacterium in Taiwan.

Triple therapy which contains a proton pump inhibitor and two antibiotics among clarithromycin, amoxicillin, and metronidazole is the most commonly used regimen for H. pylori eradication. The treatment duration is 7 to 14 days. However, the eradication rate of standard triple therapy has fallen below 80% in many countries due to the worldwide increasing prevalence of antibiotic resistant strains.

Several strategies have been proposed to increase the eradication rate in the first line therapy or as a rescue therapy, including extending the treatment duration to 14 days, increasing the doses of antibiotics, the use of four or even five drugs regimen (sequential, concomitant, quadruple or quintuple therapy), and other antibiotics such as levofloxacin. However, these therapies may increase the side effects and costs of treatment, decrease the compliance of patients and increase the rate of worldwide antibiotic resistance steadily. The WHO has listed H. Pylori as one of 16 antibiotic-resistant bacteria that have the greatest threat to human health in February, 2017.

The most commonly used oral antibiotics for the treatment of H. pylori are Amoxicillin、Clarithromycin、Metronidazole、Levofloxacin and Tetracycline.

However, with the increasing rates of antibiotic-resistance for Clarithromycin and Metronidazole, the Clarithromycin and Metronidazole were replaced by Levofloxacin as a first line or second line treatment in some area. However, the eradication rate of Levofloxacin-containing triple therapy is suboptimal in many countries. The investigators aim to compare the efficacy of different formulation between Levofloxacin Powder and Levofloxacin Solution in the Intraluminal levofloxacin therapy, and to improve the eradication efficacy of one-week Levofloxacin-containing triple therapy via the Intraluminal therapy.


Condition or disease Intervention/treatment Phase
Helicobacter Pylori Infection Drug: Levofloxacin film-coated tablet Drug: Levofloxacin intravenous solution Phase 4

Detailed Description:

During the endoscopic examination, patient is sedated with intravenous Dormicum 5mg (5mg/1ml/amp), the vital signs will be closely monitored by physiological monitor (PHILIPS SureSigns VM6). The treatment will be terminated immediately if unstable vital sign detected or if patient asks for termination. Patients will receive tests to evaluate H. pylori colonization in the gastric cardia (UFT300) and duodenal bulb (CLO). With endoscope apparatus, the gastric mucus is irrigated with acetylcysteine solution and the pH value of gastric juice will be measured with the pH test strips before irrigation and after irrigation.

The investigators randomly assigned medicaments containing different formulation (powder or solution ) of levofloxacin to dispense on the surface of gastric mucosa and duodenal mucosa of duodenal bulb. After the intraluminal therapy, patients will rest for 30 to 60 minutes and go home if the effect of sedation subsided. Patients can take meal if no abdominal discomfort. C13-Urea breath test (UBT) will be used to assess the existence of H. pylori 6 weeks after the intraluminal therapy. Patients failed to achieve intraluminal eradication of H. pylori will be randomly assigned to 7-day or 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, and esomeprazole 40 mg twice daily). The C13-UBT will be used to assess the existence of H. pylori 6 weeks after the oral antibiotic therapy. The overall eradication rates of the intraluminal therapy plus the oral antibiotics therapies will be evaluated.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

50 participants are randomly assigned to receive intraluminal eradication of H. pylori.

with medicaments containing levofloxacin powder or levofloxacin solution. Patients failed to achieve intraluminal eradication of H. pylori will be randomly assigned to 7-day or 14-day levofloxacin-containing triple therapy (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, and esomeprazole 40 mg twice daily).

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
Estimated Study Start Date : February 15, 2019
Estimated Primary Completion Date : August 14, 2020
Estimated Study Completion Date : January 27, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intraluminal Levofloxacin powder therapy
Group A Crashed powder of film-coated Levofloxacin Tablet (1 gm) for the Intraluminal therapy
Drug: Levofloxacin film-coated tablet

50 participants are randomly assigned to receive intraluminal eradication of H. pylori.

with medicaments containing levofloxacin powder or levofloxacin solution.

Other Name: Leflodal film-coated tablet

Active Comparator: Intraluminal Levofloxacin solution therapy
Group B Intravenous solution of Levofloxacin (1 gm) for the Intraluminal therapy
Drug: Levofloxacin intravenous solution

50 participants are randomly assigned to receive intraluminal eradication of H. pylori.

with medicaments containing levofloxacin powder or levofloxacin solution.

Other Name: Cravit intravenous solution




Primary Outcome Measures :
  1. Eradication rate of the intraluminal Levofloxacin therapy [ Time Frame: C13-UBT will be used to assess the existence of H. pylori 6 weeks after the intraluminal therapy. ]
    A Comparison of different formulation between Levofloxacin Powder and Levofloxacin solution


Secondary Outcome Measures :
  1. Incidence of adverse effects of the intraluminal Levofloxacin therapy [ Time Frame: within 7 days after finishing the intraluminal therapies ]
    A Comparison of different formulation between Levofloxacin Powder and Levofloxacin solution

  2. Eradication rates of 7-day or 14-day levofloxacin-containing triple therapy [ Time Frame: C13-UBT will be used to assess the existence of H. pylori 6 weeks after the levofloxacin-containing triple herapies. ]
    A Comparison of the eradication rates of 7-day or 14-day levofloxacin-containing triple therapy after intraluminal therapy

  3. The overall eradication rate [ Time Frame: 3-6 months after finishing the intraluminal therapy ]
    The overall eradication rates of the intraluminal therapy plus oral antibiotics therapies were evaluated.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients aged between 20 years and 75 years
  2. Patients have H. pylori infection and have not treated with oral antibiotics
  3. Patients are willing to receive the intraluminal therapy. The written informed consents will be obtained from all patients prior to enrollment.

Exclusion Criteria:

  1. Children and teenagers aged less than 20 years or adult greater than 75 years
  2. Contraindication for endoscopic examination or food retention in the gastric lumen.
  3. History of gastrectomy; Gastroduodenal stenosis、deformity or obstruction; Gastroduodenal malignancy, including adenocarcinoma and lymphoma
  4. Contraindication to treatment drugs: previous allergic reaction to Proton pump inhibitors, Amoxicillin, Levofloxacin, Acetylcystein, and pregnant or lactating women
  5. Severe concurrent acute or chronic illness: renal failure, decompensated cirrhosis of liver, incurable malignant disease
  6. Patients who cannot give informed consent by himself or herself.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03832465


Contacts
Layout table for location contacts
Contact: Tai-cherng Liou, MD 886-2-25433535 ext 3993 mmhltc@gmail.com

Locations
Layout table for location information
Taiwan
Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan Not yet recruiting
Taipei, Taiwan, 10449
Contact: Tai-cherng Liou, MD    886-2-25433535 ext 3990    mmhltc@gmail.com   
Sponsors and Collaborators
Mackay Memorial Hospital
Investigators
Layout table for investigator information
Principal Investigator: Tai-cherng Liou, MD Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital

Layout table for additonal information
Responsible Party: Tai-cherng Liou, MD, Principle investigator, Mackay Memorial Hospital
ClinicalTrials.gov Identifier: NCT03832465     History of Changes
Other Study ID Numbers: 18MMHIS168
First Posted: February 6, 2019    Key Record Dates
Last Update Posted: February 15, 2019
Last Verified: February 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Tai-cherng Liou, MD, Mackay Memorial Hospital:
Levofloxacin
Amoxicillin
Proton pump inhibitor
Helicobacter Pylori

Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Helicobacter Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Pharmaceutical Solutions
Levofloxacin
Ofloxacin
Anti-Infective Agents, Urinary
Anti-Infective Agents
Renal Agents
Anti-Bacterial Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors